A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Alzheimer Disease Clinical Trial

Official title:

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early (Prodromal to Mild) Alzheimer's Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04592341
• Other study ID #: WN29722
• Secondary ID: 2020-001384-87
• Status: Terminated
• Phase: Phase 2
• Start date: November 18, 2020
• Est. completion date: March 15, 2023

Study information

• Verified date: February 2024
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II, multicenter, open-label, single arm, PD study in participants with early (prodromal to mild) AD to evaluate the effect of a once weekly (Q1W) dosing regimen of gantenerumab on deposited amyloid as measured by change from baseline to Week 104 (primary) and Week 208 in brain amyloid positron emission tomography (PET). The administration of gantenerumab as a single injection of Q1W will be investigated in this study, to simplify the dosing regimen for participants.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 192
• Est. completion date: March 15, 2023
• Est. primary completion date: January 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 90 Years

Eligibility

Inclusion Criteria:

• Probable Alzheimer's Disease (AD) dementia or prodromal AD.
• Availability of a reliable study partner (non-professional caregiver) who accepts to participate in study procedure throughout the study duration
• The participant should be capable of completing all aspects of study assessments including MRI, clinical genotyping, and PET imaging, either alone or with the help of the study partner (non-professional caregiver).
• Adequate visual and auditory acuitysufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted).
• Evidence of AD pathological process, as confirmed by amyloid PET scan by qualitative read by the core/central PET laboratory.
• Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score >/=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score >/=0.5.
• If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 3 months prior to screening and until start of study treatment.
• Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug.
• Agreement not to participate in other research studies for the duration of this trial, unless these are related Roche-sponsored non-interventional studies.
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods hat result in a failure rate of < 1% per year during the treatment period and for at least 16 weeks after the final dose of study drug.

Exclusion Criteria:

• Any evidence of a condition other than AD that may affect cognition.
• History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function.
• History or presence of clinically evident cerebrovascular disease.
• History or presence of posterior reversible encephalopathy syndrome.
• History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack.
• History of severe, clinically significant CNS trauma.
• History or presence of intracranial mass that could potentially impair cognition.
• Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae.
• History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits.
• History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder.
• At risk for suicide in the opinion of the investigator.
• Alcohol and/or substance abuse or dependants in past 2 years.

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• Gantenerumab
Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.

Locations

Country	Name	City	State
Belgium	Jessa Zkh (Campus Virga Jesse)	Hasselt
Belgium	AZ Groeninge	Kortrijk
Belgium	UZ Leuven Gasthuisberg	Leuven
France	Groupement Hospitalier Est - Hôpital Neurologique; Neurologie A (U502)	Bron cedex
France	CH Pitie Salpetriere; IM2A	Paris
France	Gerontopole; Centre de Recherche clinique	Toulouse
Germany	Ambulates Gesundheitszentrum der Charité GmbH; MVZ Neurologie Campus Benjamin Franklin	Berlin
Germany	ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic	Berlin
Germany	Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie	München
Italy	Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia	Milano	Lombardia
Italy	Ospedale San Giovanni Calibita Fatebenefratell;Neurologia	Roma	Lazio
Italy	Ospedale Cardinale Panico; Dip.Ricerca Clinica in Neurologia ? UO Malattie Neurodegenerative	Tricase (LE)	Puglia
Poland	NZOZ Vitamed	Bydgoszcz
Poland	Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak.	Lublin
Poland	Senior Sp. Z O.O. Poradnia Psychogeriatryczna	Sopot
Poland	Centrum Medyczne Euromedis Sp. z o.o.	Szczecin
Poland	Centrum Medyczne NeuroProtect	Warszawa
Poland	NZOZ WCA	Wroc?aw
Spain	Policlínica Guipuzcoa; Servicio de Neurología	Donostia-san Sebastian	Guipuzcoa
Spain	Hospital Universitario 12 de Octubre; Servicio de Neurologia	Madrid
Spain	Hospital Universitario de la Princesa; Servicio de Neurologia	Madrid
Spain	Hospital Quiron de Madrid; Servicio de Neurologia	Pozuelo de Alarcon	Madrid
Spain	Hospital Universitari i Politecnic La Fe; Servicio de Neurología	Valencia
United Kingdom	Re-Cognition	Birmingham
United Kingdom	Fritchie Centre	Cheltenham
United Kingdom	Ninewells Hospital	Dundee
United Kingdom	Charing Cross Hospital; Imperial Memory Unit, Level 10 West	London
United States	JEM Research LLC	Atlantis	Florida
United States	Center for Advanced Research & Education	Gainesville	Georgia
United States	ClinCloud, LLC	Maitland	Florida
United States	Renstar Medical Research	Ocala	Florida
United States	Summit Research Network Inc.	Portland	Oregon
United States	Alzheimer?s Research and Treatment Center	Wellington	Florida
United States	Abington Neurological Associates Willow Grove	Willow Grove	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  Italy,  Poland,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Brain Amyloid Load at Week 104 as Measured by [18F] Florbetaben Positron Emission Tomography (PET) Scan	Screening amyloid PET scan was considered baseline evaluation.Brain amyloid load was quantified in terms of Standardized Uptake Value Ratio (SUVR),defined as ratio of tracer uptake in cortical composite target region of interest(ROI)to tracer uptake in reference ROI.Composite region: frontal,parietal,temporal,posterior cingulate cortex,anterior cingulate cortex. Reference ROI (whole cerebellum) was represented by weighted average of Cerebellum Ventral,Cerebellum Dorsal (left/right), Cerebellar White Matter.SUVR linearly transformed to standardized Centiloid Scale (CL) using formula CL=175.6xSUVR-174.2.CL ranges from <0 to >100, anchor points are 0=high-certainty amyloid negative scan and 100=amount of global amyloid deposition found in typical AD scan.	Baseline, Week 104
Secondary	Number of Caregiver or Study Partner With Responses to Home Administration Questionnaire (HAQ)	HAQ comprised 4 items completed by study partner capturing confidence (Q1), convenience (Q2), ease of use (Q3), and overall satisfaction (Q4) with administering medication. Response options Q1: Not at all confident, somewhat confident, confident, very confident; Q2: Not at all convenient, somewhat convenient, convenient, very convenient; Q3: Not at all easy, somewhat easy, easy, very easy; Q4:Not at all satisfied, somewhat satisfied, satisfied, very satisfied.	Weeks 36, 52, 76, 104
Secondary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	AE: any untoward medical occurrence in participant administered pharmaceutical product, which does not necessarily have a causal relationship with treatment. Also, any unfavorable, unintended sign, symptom, or disease temporally associated with use of medicinal product, whether or not considered related to it. SAE: any AE that was fatal, life threatening, required prolonged inpatient hospitalization, resulted in significant disability or resulted in a congenital anomaly to mother exposed to study treatment. This was a single-arm study and all participants received gantenerumab according to predefined universal up-titration scheme as follows: 120 mg Q4W (Day 1, Week (W) 4, and W8), then 255 mg Q4W (W 12, 16, and 20), then 255 mg Q2W for 12 weeks (W 24, 26, 28, 30, 32, and 34), followed by target dose of 255 mg Q1W (W 36 to 104). Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study.	From day of first dose up to 16 weeks after the last dose (up to 120 weeks)
Secondary	Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)	C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, & attempts with actual/potential lethality. Categories have binary responses (yes/no) & include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods(Not Plan)without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal);Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.	From day of first dose up to 16 weeks after the last dose (up to 120 weeks)
Secondary	Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)	ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. The occurrences of imaging abnormalities in vasogenic edema and sulcal effusions (ARIA-E) were evaluated.	From day of first dose up to 16 weeks after the last dose (up to 120 weeks)
Secondary	Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by Magnetic Resonance Imaging (MRI)	ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.	From day of first dose up to 16 weeks after the last dose (up to 120 weeks)
Secondary	Number of Participants With Injection-Site Reactions (ISR)	An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Injection reactions (local and systemic) were defined as AEs that occured during or within 24 hours after study drug administration that were judged to be related to the study drug injection.	From day of first dose up to 16 weeks after the last dose (up to 120 weeks)
Secondary	Number of Participants With Treatment-emergent Anti-Drug Antibodies to Gantenerumab	A participant with an ADA assay result from at least one post-baseline sample was defined as a post-baseline evaluable participant. Treatment Emergent ADA was defined as a participant with a negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result, or a participant with a positive ADA result at baseline who has at least one post-baseline titer results with at least a >2.5-fold increase in titer compared to baseline greater than the baseline titer result.	From day of first dose up to 16 weeks after the last dose (up to 120 weeks)
Secondary	Plasma Concentration of Subcutaneous (SC) Gantenerumab at Specified Timepoints		Day 4 of Week 1, Week 24, 36, 52, and 76
Secondary	Change in Brain Amyloid Based on Different Dosing Frequency	The change from baseline at Week 52 using the once-weekly dosing frequency was analysed using the centiloid scale. The centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. The range of centiloid values can be below 0 (negative) and greater than 100.	Baseline up to Week 52